Hagens Berman Sobol Shapiro Cases

ACTIMMUNE

Date Filed: May 8, 2008

Court: U.S. District Court

Location: Northern District of California

Hagens Berman filed a proposed class-action lawsuit against InterMune and Genentech, the marketers and manufacturers of ACTIMMUNE, alleging fraud and deception in the marketing and sale of the drug.

The lawsuit claims the company deceptively marketed the drug as treatment for idiopathic pulmonary fibrosis (IPF), a deadly disease with no known cause or cure. The lawsuit contends InterMune created and distributed materials that falsely claimed the drug had been shown to extend the lives of IPF patients and could reduce mortality by 70 percent in patients with mild to moderate disease.

The disease affects more than 80,000 people in the United States and prohibits the lungs from expanding during breathing, decreasing the availability of oxygen to the bloodstream.

InterMune, the pharmaceutical marketing company, recently paid $37 million in restitution to federal and state third-party payors after a federal criminal felony misconduct charge relating to its marketing tactics with ACTIMMUNE media sources reported.

This lawsuit is filed on behalf of consumers and private payors who purchased the drug.

If you purchased the drug or made co-payments with your insurance company ACTIMMUNE, you are eligible to join this case. You can reach HBSS at info@hbsslaw.comif you have additional questions or concerns about the case.